title: The association between serum uric acid levels, metabolic syndrome and cardiovascular disease in middle aged and elderly Chinese: results from the DYSlipidemia International Study.
abstract: BACKGROUND
  To explore the association between serum uric acid (SUA) levels, metabolic syndrome (MetS) and cardiovascular disease (CVD) in patients treated with lipid-lowering agents from multiple centers in China.
  
  
  METHODS
  We investigated 15,478 participants who had been documented with recorded SUA in the DYSlipidemia International Study which included 25,697 patients, aged 45 years old or older, who were treated with lipid-lowering agents from 122 centers between April 2012 and October 2012. Logistic regression analysis was performed to examine the association between SUA levels, MetS and CVD.
  
  
  RESULTS
  After adjusting for multi-variables, hyperuricemia (the highest category of SUA level) showed a significantly higher risk of MetS compared to the lowest category[according to NCEP-ATPIII criteria, odds ratio (OR) 1.51, 95 % confidence interval (CI) (1.30,1.74) in men, OR 2.35 95 % CI (2.00,2.75) in women; and according to IDF criteria, OR 1.40 95 % CI (1.20,1.63) in men, OR 1.65 95 % CI (1.41,1.94) in women]. In addition, elevated SUA concentration was shown to be associated with coronary heart disease (CHD) (OR 1.26 95 % CI (1.09, 1.45) in men, and OR 1.27, 95 % CI (1.07, 1.50) in women) and heart failure (HF) (OR 1.61 95 % CI (1.15, 2.24) in men, and OR 1.91, 95 % CI (1.29, 2.82) in women).
  
  
  CONCLUSIONS
  Our research suggested a positive association between SUA levels and MetS in Chinese patients receiving lipid-lowering therapy. Elevated SU levels were positively associated independently of measured confounders to CHD and HF.
authors.affiliation: Department of Endocrinology, Chinese PLA General Hospital, No.28, Fuxing Rd, Haidian District, Beijing, 100853, P.R. China. tianyf1988@163.com.|Department of Endocrinology, Xinqiao Hospital, Third Military Medical University, No.183, Xinqiao Rd, Shapingba District, Chongqing, 400037, P.R. China. tianyf1988@163.com.
authors.forename: Yongfeng
authors.initials: Y
authors.lastname: Tian
authors.affiliation: Department of Endocrinology, Chinese PLA General Hospital, No.28, Fuxing Rd, Haidian District, Beijing, 100853, P.R. China. cycon_ck@yeah.net.
authors.forename: Kang
authors.initials: K
authors.lastname: Chen
authors.affiliation: Department of Endocrinology, Chinese PLA General Hospital, No.28, Fuxing Rd, Haidian District, Beijing, 100853, P.R. China. xiezongy@163.com.
authors.forename: Zongyan
authors.initials: Z
authors.lastname: Xie
authors.affiliation: Department of Endocrinology, Chinese PLA General Hospital, No.28, Fuxing Rd, Haidian District, Beijing, 100853, P.R. China. angela0932@163.com.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Fang
authors.affiliation: Department of Endocrinology, Chinese PLA General Hospital, No.28, Fuxing Rd, Haidian District, Beijing, 100853, P.R. China. wanghaibin2307@126.com.
authors.forename: Haibin
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of Endocrinology, Chinese PLA General Hospital, No.28, Fuxing Rd, Haidian District, Beijing, 100853, P.R. China. nieyi0730@163.com.
authors.forename: Yi
authors.initials: Y
authors.lastname: Nie
authors.affiliation: Department of Cardiology, Peking University People's Hospital, No.11, Xi Zhi Men Nan Da Jie, Xicheng District, Beijing, 100044, P.R. China. dayi.hu@medmail.com.cn.
authors.forename: Dayi
authors.initials: D
authors.lastname: Hu
authors.affiliation: Department of Endocrinology, Chinese PLA General Hospital, No.28, Fuxing Rd, Haidian District, Beijing, 100853, P.R. China. yimingmu301@126.com.
authors.forename: Yiming
authors.initials: Y
authors.lastname: Mu
mesh_terms: D000368:Aged; D002318:Cardiovascular Diseases / Q000097:blood* / Q000453:epidemiology; D002681:China / Q000453:epidemiology; D015331:Cohort Studies; D003327:Coronary Disease / Q000097:blood / Q000453:epidemiology; D050171:Dyslipidemias / Q000097:blood* / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D006801:Humans; D033461:Hyperuricemia / Q000097:blood* / Q000453:epidemiology; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000453:epidemiology; D008875:Middle Aged; D016017:Odds Ratio; D011446:Prospective Studies; D012307:Risk Factors; D014527:Uric Acid / Q000097:blood*
chemical_list: D000960:Hypolipidemic Agents; D014527:Uric Acid